Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits

Abstract

LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration.

What is claimed is: 
     
         1 . A kit comprising one or more initial doses of an LHRH analogue in one or more containers, each in an amount sufficient to effect hormonal castration, and one or more maintenance doses of an LHRH antagonist in one or more containers, each in an amount insufficient to achieve and/or maintain hormonal castration. 
     
     
         2 . The kit according to  claim 1 , wherein the LHRH antagonist is selected from the group consisting of abarelix, antide, azaline B, A-75998, cetrorelix, degarelix, detirelix, ozarelix (D-63153), ganirelix, Nal-Glu-Antagonist, ramorelix, and RS-68439, teverelix. 
     
     
         3 . The kit according to  claim 1 , wherein the LHRH analogue is an LHRH antagonist selected from the group consisting of abarelix, antide, azaline B, A-75998, cetrorelix, degarelix, detirelix, ozarelix (D-63153), ganirelix, Nal-Glu-Antagonist, ramorelix, RS-68439, teverelix. 
     
     
         4 . The kit according to  claim 1 , wherein the LHRH analogue is an LHRH agonist and selected from the group consisting of goserelin, leuprorelin (leuprolide), triptorelin, buserelin, nafarelin, historelin, and deslorelin. 
     
     
         5 . The kit according to  claim 1 , wherein each maintenance dose of the LHRH antagonist independently is 1 mg to 65 mg. 
     
     
         6 . The kit according to  claim 5 , wherein each maintenance dose of the LHRH antagonist independently is 5 mg to 50 mg. 
     
     
         7 . The kit according to  claim 6 , wherein each maintenance dose of the LHRH antagonist independently is 5 mg to 40 mg. 
     
     
         8 . The kit according to  claim 7 , wherein each maintenance dose of the LHRH antagonist independently is 10 mg to 30 mg. 
     
     
         9 . The kit according to  claim 8 , wherein each maintenance dose of the LHRH antagonist independently is 15 mg to 25 mg. 
     
     
         10 . The kit according to  claim 1 , wherein each initial dose of the LHRH antagonist independently is 65 mg to 300 mg. 
     
     
         11 . The kit according to  claim 10 , wherein each initial dose of the LHRH antagonist independently is 100 mg to 250 mg 
     
     
         12 . The kit according to  claim 11 , wherein each initial dose of the LHRH antagonist independently is 150 mg to 200 mg 
     
     
         13 . The kit according to  claim 1 , wherein the kit is for use in the treatment or prophylaxis of hormone-dependent cancers selected from the group consisting of: prostate cancer, prostate carcinoma and/or advanced prostate carcinoma. 
     
     
         14 . The kit according to  claim 1 , wherein the kit is for use in the treatment or prophylaxis of prostate cancer. 
     
     
         15 . The kit according to  claim 1 , wherein the kit is for use in the treatment or prophylaxis of prostate carcinoma. 
     
     
         16 . The kit according to  claim 1 , wherein the kit is for use in the treatment or prophylaxis of advanced prostate carcinoma.